Ocular Therapeutix’s (OCUL) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Ocular Therapeutix (NASDAQ:OCUL) in a report issued on Tuesday morning,Benzinga reports. They currently have a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Ocular Therapeutix’s Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.29) EPS and FY2025 earnings at ($1.18) EPS.

Ocular Therapeutix Stock Performance

OCUL opened at $7.34 on Tuesday. The company’s 50 day moving average is $7.76 and its 200 day moving average is $8.87. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -5.56 and a beta of 1.22. Ocular Therapeutix has a 12-month low of $4.06 and a 12-month high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The business had revenue of $17.08 million for the quarter, compared to analysts’ expectations of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. On average, equities research analysts predict that Ocular Therapeutix will post -0.98 EPS for the current year.

Insiders Place Their Bets

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the transaction, the insider now owns 3,520,318 shares of the company’s stock, valued at $24,184,584.66. The trade was a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Donald Notman sold 11,119 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total transaction of $86,839.39. Following the completion of the sale, the insider now directly owns 193,444 shares of the company’s stock, valued at approximately $1,510,797.64. This trade represents a 5.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,895 shares of company stock worth $283,772 over the last quarter. 3.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of OCUL. GF Fund Management CO. LTD. bought a new stake in Ocular Therapeutix during the fourth quarter valued at about $28,000. Atlas Capital Advisors Inc. bought a new stake in Ocular Therapeutix during the 4th quarter valued at approximately $43,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Ocular Therapeutix by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 1,015 shares in the last quarter. AlphaQuest LLC bought a new position in Ocular Therapeutix in the 4th quarter worth approximately $53,000. Finally, Capital Performance Advisors LLP purchased a new stake in Ocular Therapeutix during the 3rd quarter valued at approximately $70,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.